Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,151 recruiting studies in this area right now.
By phase
- Not applicable9,506
- Phase 24,400
- Phase 12,662
- Phase 1/Phase 21,649
- Phase 31,391
- Phase 2/Phase 3283
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer647
- Cancer634
- Colorectal Cancer480
- Lung Cancer416
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer288
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer207
- Advanced Solid Tumors201
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center288
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,408
- Texas635
- Arizona512
- Florida434
- Alabama427
- New York405
- Massachusetts342
- Maryland330
- New Jersey269
- Pennsylvania234
Recruiting studies20,151 total
- NCT06742515RecruitingPhase 2
Blinatumomab with lower-dose chemo for B-ALL
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hangzhou, ZhejiangAges 15–59 - NCT06742463RecruitingPhase 2
VHAG for relapsed or refractory T-cell acute leukemia
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hangzhou, ZhejiangAges 14–74 - NCT06742021Recruiting
MRI test to predict immune therapy response in lung cancer
This trial uses a special MRI technique (4D FreeBreathing) to see if it can predict how well immune therapy or targeted therapy works for your lung cancer. It may help doctors choose the best treatment for you more quickly.
Kunming, YunnanAges 18–75 - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT03866525RecruitingPhase 1/Phase 2
Test an oncolytic virus treatment for solid tumors
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Beijing, Beijing MunicipalityAges 18–75 - NCT05359939Recruiting
MRI, CT, and PET scans compared for liver cancer
This study compares different scan types (MRI, CT, and two PET scans) in people with hepatocellular carcinoma (a primary liver cancer). It may help doctors figure out which scan gives the most useful information for diagnosis and treatment planning.
AarhusAges 18 years+ - NCT07549256RecruitingPhase 2
Cannabidiol for pain relief in advanced prostate cancer
This trial tests a cannabis-derived medicine called cannabidiol (CBD) for pain relief in men with advanced prostate cancer that has stopped responding to standard treatments. The goal is to see if CBD can help reduce pain when other options have been exhausted.
GistrupAges Any age - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT05698459RecruitingPhase 1
Study of a virus treatment delivered into liver arteries
This Phase 1 study tests an oncolytic (tumor-attacking) virus given directly into liver arteries using a catheter. It’s for people with advanced liver cancer who have already tried standard treatments or can’t have them, aiming to assess safety and early anti-cancer activity.
Wuhan, HubeiAges 18–75 - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if a prostate biopsy is needed
This study tests a new blood test (Proclarix) that may help doctors decide if a prostate biopsy is needed. It is for men with a slightly elevated PSA who are already considering a biopsy.
San Diego, CaliforniaAges 40–75 - NCT07545356RecruitingPhase 1
Testing KIVU-305 for Advanced Solid Tumors
This study tests a new cancer drug called KIVU-305 in people with advanced or metastatic solid tumors (cancer that has spread) that haven't responded to standard treatments. The drug is designed to target cancer cells while minimizing harm to healthy cells.
Sydney, New South WalesAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Phoenix, ArizonaAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07551336RecruitingPhase 1
CAR-NK cells for recurrent glioblastoma and high-grade brain tumors
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
Shenzhen, GuangdongAges 18–75 - NCT07548177RecruitingPhase 2
Combination drug study for advanced soft tissue sarcoma
This study tests two cancer drugs (benmelstobart and anlotinib) together to treat alveolar soft part sarcoma, a rare soft tissue cancer that has spread or cannot be surgically removed. The drugs work by boosting the immune system and blocking tumor blood vessel growth.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+ - NCT07549412RecruitingPhase 3
New chemotherapy drugs for advanced colorectal cancer
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Lone Tree, ColoradoAges 18 years+ - NCT07544446Recruiting
Early Mental Health Support for People Starting Cancer Treatment
This study looks at whether talking with a mental health specialist early on—right after a cancer diagnosis—helps people manage treatment better. You'd meet with a psycho-oncologist (a counselor trained in cancer care) and answer some questions about how you're doing.
BaselAges 18 years+ - NCT07545265RecruitingPhase 1/Phase 2
SKB565 injection for advanced solid cancers
This study tests SKB565, a new injectable cancer treatment, in people with advanced solid tumors (cancer that has spread or hasn't responded to standard treatments). The trial aims to find the right dose and learn how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07545122RecruitingPhase 1
Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Wahroonga, New South WalesAges 18 years+ - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Scottsdale, ArizonaAges 18 years+ - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,151 recruiting oncology studies from the U.S. registry right now, out of 30,040 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.